FindTrial
Sign In

Use of angiotensin receptor neprilysin inhibitor in patients with heart failure and reduced ejection fraction in China: a real-world study

Use of angiotensin receptor neprilysin inhibitor in patients with heart failure and reduced ejection fraction in China: a real-world study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038716
Enrollment
Unknown
Registered
2020-09-29
Start date
2020-10-16
Completion date
Unknown
Last updated
2020-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

Case series:Nil

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
19 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) patients aged more than 18 years old; 2) Age, sex, left ventricular ejection fraction (LVEF), and 12 months follow-up were not missing; 3) LVEF<=40%; 4) Inpatients enrolled in the Heart Failure Cneter Program from Jan 1, 2017 to Dec 31, 2019.

Exclusion criteria

Exclusion criteria: 1) Dearth in hospitals; 2) Patients with valvular heart disease; 3) Patients with cancers; 4)angiotensin receptor neprilysin inhibitor uses was not recorded or "other".

Design outcomes

Primary

MeasureTime frame
1 year cardiovascular death or readmission;—

Secondary

MeasureTime frame
1 year all-cause death rate;1 year cardiovascular readmission;1 year heart failure readimission;—

Countries

China

Contacts

Public ContactJiefu Yang

Beijing Hospital

yangjiefu2011@126.com+86 13601292259

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026